Literature DB >> 8318407

Nuclear DNA content and morphological characteristics in the prognosis of adrenocortical carcinoma.

H R Haak1, C J Cornelisse, J Hermans, L Cobben, G J Fleuren.   

Abstract

Prognostic factors are needed for the management of patients with adrenocortical tumours. For this reason, the nuclear DNA content of patients with adrenocortical tumours was analysed by flow cytometry. The relationships between nuclear DNA content, histological indices, and clinical parameters were studied. DNA ploidy could be evaluated in 54 carcinoma and 31 adenoma patients. Twenty-one (68%) of the adenomas, and 6 (11%) of the carcinomas, were DNA diploid. Hypo/Hyperdiploidy was found in 5 (16%) of the adenomas, and 15 (28%) of the carcinomas. The remaining patients had a DNA index above 1.40. A shorter survival was found in patients with diploid carcinomas (P < 0.05). A longer disease-free survival was seen in patients with hypo/hyperdiploid carcinomas (P < 0.05). Nuclear DNA content was not related to the histological index, nor to clinical parameters. We conclude that nuclear DNA content is related to (disease-free) survival of patients with adrenocortical carcinomas. An adenoma-carcinoma sequence may be present in the adrenal cortex. In adrenocortical tumours ploidy evolution appears to be different than that observed in other solid tumours.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8318407      PMCID: PMC1968309          DOI: 10.1038/bjc.1993.304

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  22 in total

1.  Adrenocortical carcinoma: nuclear deoxyribonucleic acid ploidy studied by flow cytometry.

Authors:  Y Hosaka; L M Rainwater; C S Grant; W F Young; G M Farrow; J A van Heerden; M M Lieber
Journal:  Surgery       Date:  1987-12       Impact factor: 3.982

2.  Flow cytometric DNA analysis of neuroblastoma. Correlation with histology and clinical outcome.

Authors:  T Gansler; J Chatten; M Varello; G R Bunin; B Atkinson
Journal:  Cancer       Date:  1986-12-01       Impact factor: 6.860

Review 3.  Adrenal cortical carcinoma.

Authors:  N A Samaan; R C Hickey
Journal:  Semin Oncol       Date:  1987-09       Impact factor: 4.929

4.  The treatment of adrenocortical carcinoma with o,p'-DDD: prognostic implications of serum level monitoring.

Authors:  H van Slooten; A J Moolenaar; A P van Seters; D Smeenk
Journal:  Eur J Cancer Clin Oncol       Date:  1984-01

5.  Influence of cellular DNA content on survival in differentiated thyroid cancer.

Authors:  H Joensuu; P Klemi; E Eerola; J Tuominen
Journal:  Cancer       Date:  1986-12-01       Impact factor: 6.860

6.  Different karyotypic patterns in early and advanced stage neuroblastomas.

Authors:  Y Kaneko; N Kanda; N Maseki; M Sakurai; Y Tsuchida; T Takeda; I Okabe; M Sakurai
Journal:  Cancer Res       Date:  1987-01-01       Impact factor: 12.701

7.  Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors.

Authors:  L M Weiss
Journal:  Am J Surg Pathol       Date:  1984-03       Impact factor: 6.394

8.  Tumor ploidy as a major prognostic factor in advanced ovarian cancer.

Authors:  C J Rodenburg; C J Cornelisse; P A Heintz; J Hermans; G J Fleuren
Journal:  Cancer       Date:  1987-01-15       Impact factor: 6.860

9.  DNA ploidy and survival in breast cancer patients.

Authors:  C J Cornelisse; C J van de Velde; R J Caspers; A J Moolenaar; J Hermans
Journal:  Cytometry       Date:  1987-03

10.  Morphologic characteristics of benign and malignant adrenocortical tumors.

Authors:  H van Slooten; A Schaberg; D Smeenk; A J Moolenaar
Journal:  Cancer       Date:  1985-02-15       Impact factor: 6.860

View more
  6 in total

1.  Giant adrenal pseudocyst harbouring adrenocortical cancer.

Authors:  Michael Wilkinson; Deirdre Mary Fanning; James Moloney; Hugh Flood
Journal:  BMJ Case Rep       Date:  2011-09-26

Review 2.  Adrenal cystic lesions: report of 12 surgically treated cases and review of the literature.

Authors:  R Bellantone; A Ferrante; M Raffaelli; M Boscherini; C P Lombardi; F Crucitti
Journal:  J Endocrinol Invest       Date:  1998-02       Impact factor: 4.256

3.  Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?

Authors:  Electron Kebebew; Emily Reiff; Quan-Yang Duh; Orlo H Clark; Alex McMillan
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

Review 4.  Discerning malignancy in resected adrenocortical neoplasms.

Authors:  H Sasano; T Suzuki; T Moriya
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

Review 5.  Assessment of malignancy in adrenal cortical tumors.

Authors:  Anne Marie McNicol
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

6.  Assessment of the role of transcript for GATA-4 as a marker of unfavorable outcome in human adrenocortical neoplasms.

Authors:  Angela S Barbosa; Luciano R Giacaglia; Regina M Martin; Berenice B Mendonca; Chin J Lin
Journal:  BMC Endocr Disord       Date:  2004-07-07       Impact factor: 2.763

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.